exclude other unusual or non-recurring items that are evaluated on an
individual basis. Amicus' evaluation of whether to exclude an item for
purposes of determining its non-GAAP financial measures considers both
the quantitative and qualitative aspects of the item, including, among
other things (i) its size and nature, (ii) whether or not it relates
to its ongoing business operations, and (iii) whether or not Amicus
expects it to occur as part of its normal business on a regular basis.
Items excluded for purposes of determining non-GAAP net loss and
diluted net loss per common share include deemed dividends, preferred
stock accretion, and changes in the fair value of warrant liability.
Conference Call and Webcast
Amicus Therapeutics will host a conference call and webcast today, Monday, November 3, 2008, at 5:00 P.M. EST to review financial results and recent developments. Interested participants and investors may access the conference call at 5 P.M. EST by dialing 877-419-6591 (U.S./Canada) or 719-325-4858 (international).
An audio webcast can also be accessed via the investor section of the Amicus Therapeutics Web site at http://www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, a webcast replay will remain available in the Investors section of the Amicus Therapeutics Web site for 90 days.
A telephonic replay of the call will be available for seven days beginning at 8 p.m. EST. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 4499321.
|SOURCE Amicus Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved